Sectoral Asset Management Inc. lessened its position in Kura Oncology, Inc. (NASDAQ:KURA – Free Report) by 86.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 54,110 shares of the company’s stock after selling 341,762 shares during the quarter. Sectoral Asset Management Inc.’s holdings in Kura Oncology were worth $562,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of Kura Oncology by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock valued at $57,224,000 after purchasing an additional 39,105 shares during the period. Jacobs Levy Equity Management Inc. lifted its stake in shares of Kura Oncology by 101.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after purchasing an additional 1,121,228 shares during the period. Qube Research & Technologies Ltd lifted its stake in shares of Kura Oncology by 63.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock valued at $11,032,000 after purchasing an additional 738,761 shares during the period. UBS Group AG raised its stake in Kura Oncology by 118.3% during the fourth quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock valued at $11,014,000 after buying an additional 574,455 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. raised its stake in Kura Oncology by 317.9% during the fourth quarter. Nan Fung Trinity HK Ltd. now owns 964,880 shares of the company’s stock valued at $10,025,000 after buying an additional 734,000 shares during the last quarter.
Kura Oncology Price Performance
Shares of NASDAQ:KURA opened at $11.25 on Monday. Kura Oncology, Inc. has a 12-month low of $5.45 and a 12-month high of $12.49. The stock has a fifty day simple moving average of $9.01 and a two-hundred day simple moving average of $9.45. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $998.66 million, a price-to-earnings ratio of -3.36 and a beta of 0.32.
Analyst Ratings Changes
A number of brokerages have issued reports on KURA. Wedbush lowered their price objective on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Friday, March 6th. Mizuho lowered their price objective on Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, March 24th. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. UBS Group reiterated a “buy” rating and set a $15.00 price objective (down from $16.00) on shares of Kura Oncology in a research note on Friday, March 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a research note on Tuesday, April 21st. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Kura Oncology has an average rating of “Moderate Buy” and a consensus price target of $26.38.
Get Our Latest Analysis on Kura Oncology
Kura Oncology Profile
Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.
The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.
Featured Stories
- Five stocks we like better than Kura Oncology
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology, Inc. (NASDAQ:KURA – Free Report).
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
